Lercanidipine hydrochloride
Names
[ CAS No. ]:
132866-11-6
[ Name ]:
Lercanidipine hydrochloride
[Synonym ]:
Renovia
Vasodip
Carmen
Lercadip
Lercan
Lercaton
2-((3,3-diphenylpropyl)methylamino)-1,1-dimethylethyl methyl (4RS)-2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate monohydrochloride
Lercapin
Lerdip
Cardiovasc
Lercanidipine hydrochloride
Corifeo
Lercanidipine hydrochloride hemihydrate
Lerkamen
Zanicor
1-[(3,3-Diphenylpropyl)(methyl)amino]-2-methylpropan-2-yl methyl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate hydrochloride (1:1)
Masnidipine hydrochloride
REC 15-2375
1-[(3,3-Diphenylpropyl)(methyl)amino]-2-methyl-2-propanyl methyl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydro-3,5-pyridinedicarboxylate hydrochloride (1:1)
Lerzam
MFCD07773089
3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-, 2-[(3,3-diphenylpropyl)methylamino]-1,1-dimethylethyl methyl ester, hydrochloride (1:1)
Zandip
Zanidip
Lercanidipine (hydrochloride)
Biological Activity
[Description]:
[Related Catalog]:
[References]
[Related Small Molecules]
Chemical & Physical Properties
[ Boiling Point ]:
712.5ºC at 760mmHg
[ Melting Point ]:
175-177ºC
[ Molecular Formula ]:
C36H42ClN3O6
[ Molecular Weight ]:
648.188
[ Flash Point ]:
384.7ºC
[ Exact Mass ]:
647.276184
[ PSA ]:
113.69000
[ LogP ]:
8.13240
[ Vapour Pressure ]:
3.77E-20mmHg at 25°C
[ Storage condition ]:
2-8°C
MSDS
Safety Information
[ Symbol ]:
GHS06
[ Signal Word ]:
Danger
[ Hazard Statements ]:
H301
[ Precautionary Statements ]:
P301 + P310
[ Personal Protective Equipment ]:
Eyeshields;Faceshields;Gloves;type P2 (EN 143) respirator cartridges
[ Hazard Codes ]:
T: Toxic;
[ Risk Phrases ]:
R25
[ Safety Phrases ]:
S36/37-S45
[ RIDADR ]:
UN 2811
Synthetic Route
Precursor & DownStream
Precursor
DownStream
Articles
Eur. J. Clin. Pharmacol. 68(7) , 1043-7, (2012)
The aim of this study was to compare the systemic exposure of lercanidipine (Zanidip) after oral administration in the fasted state and 15 min before food intake (meals) to investigate if the recommen...
Rationale for the use of a fixed-dose combination in the management of hypertension: efficacy and tolerability of lercanidipine/enalapril.Clin. Drug Investig. 30(12) , 843-54, (2010)
Hypertension, a significant factor in the development of cerebrovascular disorders, heart disease and renal failure, is a common disorder worldwide. Despite the availability of a wide range of antihyp...
Lercanidipine rescues hippocampus pyramidal neurons from mild ischemia-induced delayed neuronal death in SHRSP.Cell. Mol. Neurobiol. 31(4) , 561-7, (2011)
Stroke-prone spontaneously hypertensive rats (SHRSPs) are vulnerable to ischemia and delayed neuronal death (DND) of hippocampus pyramidal cells when bilateral carotid arteries are occluded for only 1...